Skip to main content
. Author manuscript; available in PMC: 2011 Sep 27.
Published in final edited form as: Circulation. 2011 Sep 13;124(11 Suppl):S62–S69. doi: 10.1161/CIRCULATIONAHA.110.002543

Table 1.

Pre-operative Demographics and Intra-operative Variables in Patients Receiving Aprotinin or Lysine Analogues

Aprotinin(N=325) Lysine Analogues*(N=456) p-value
Patient History Profile
LV Ejection Fraction (%) 47.5 52.1 0.0001
BSA (m2) 2.0±0.26 2.0±0.24 0.92
Age 61.2±15.2 63.3±13.2 0.04
Gender (M) % 63.2 64.4 0.74
Current Smoker (Y) % 29.4 23.3 0.0004
Diabetes (Y) % 24.9 44.7 <0.0001
Hypercholesterolemia(Y) % 51.3 61.8 0.003
History of Renal Failure (Y)% 7.7 5.2 0.14
Chronic Obstructive Pulmonary 12.2 15.1 0.23
Disease (Y)%
Peripheral Vascular Disease ( Y)% 12.5 12.1 0.88
Cerebrovascular Disease (Y)% 12.2 13.0 0.74
Previous Myocardial Infarction (Y)% 20.8 23.1 0.43
EuroScore Mean (SD) 7.0(3.3) 5.3(3.1) <0.0001
Pre-operative cardiac medications
Beta Blockers (Y) % 61.4 66.1 0.17
Ace Inhibitors (Y) % 40.7 16.2 <0.0001
Nitrates (Y) % 7.4 9.9 0.22
AntiArrythmics (Y) % 11.9 8.6 0.13
Antiplatelet (Y) % 3.6 5.4 0.22
Diuretic (Y) % 19.0 6.5 <0.0001
Inotropes (Y )% 7.1 2.2 0.0006
Steroids (Y )% 5.3 5.2 0.92
Aspirin (Y) % 47.5 27.4 <0.0001
Anticoagulant (Y) % 42.1 57.9 0.73
Procedure Type <0.0001
CABG (%) 41.2 65.8
Valve (%) 41.9 27.2
Transplant/Other (%) 16.9 7.0
Intra/Post Operative Profile
Cardiopulmonary Bypass Time (min) 144.6±63.0 111.4±53.8 <0.0001
Cross Clamp Time (min) 92.1±34.9* 79.7±39.0 <0.0001
Total Length of Stay (days) 9 [6, 12] 8 [5, 12] 0.002
Post operative Length of Stay (days) 7 [5, 10] 6 [5. 9] 0.005
*

-Lysine Analogues: tranexamic acid or aminocaproic acid. Values presented as mean+/− standard deviation or percent. Length of stay presented as median value [interquartile range]. P-values computed from t-tests (with Satterthwaite approximation) for mean values, chi-Square for frequencies, and Wilcoxon Rank sum for length of stay.